Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Percival

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|February 20, 2020
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndromeFrances Linzee Mabrey, Kelda M Gardner, Kathleen Shannon Dorcy, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
Real-World Impact of the Accelerate PhenoTest BC Kit on Patients With Bloodstream Infections in the Improving Outcomes and Antimicrobial Stewardship Study: A Quasiexperimental Multicenter StudyAmira A Bhalodi, Shawn H MacVane, Bradley Ford, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Leukemia|May 31, 2017
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 studyA B Halpern, M Othus, E M Huebner, et al.
JCO Oncology Practice|May 6, 2020
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle StrategyMary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|February 20, 2020
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndromeFrances Linzee Mabrey, Kelda M Gardner, Kathleen Shannon Dorcy, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
Real-World Impact of the Accelerate PhenoTest BC Kit on Patients With Bloodstream Infections in the Improving Outcomes and Antimicrobial Stewardship Study: A Quasiexperimental Multicenter StudyAmira A Bhalodi, Shawn H MacVane, Bradley Ford, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Pageof 12